RVX Share Price

Open 1.29 Change Price %
High 1.33 1 Day -0.03 -2.26
Low 1.25 1 Week 0.00 0.00
Close 1.30 1 Month -0.26 -16.67
Volume 49380 1 Year -0.51 -28.18
52 Week High 2.41
52 Week Low 1.23
RVX Important Levels
Resistance 2 1.37
Resistance 1 1.34
Pivot 1.29
Support 1 1.26
Support 2 1.23
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
ECA 15.09 4.43%
ECA 15.09 4.43%
ECA 15.09 4.43%
SC 60.83 -0.44%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
GGA 0.06 20.00%
ANX 0.07 16.67%
ANX 0.07 16.67%
COM 2.27 14.07%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
NXJ 2.35 -10.31%
NXJ 2.35 -10.31%
RN 0.09 -10.00%
RN 0.09 -10.00%
CTU-A 0.19 -9.52%
TNP 0.90 -9.09%
TNP 0.90 -9.09%
TNX 0.34 -8.11%
QEC 0.74 -7.50%
More..

Resverlogix Corp (TSE: RVX)

RVX Technical Analysis 5
As on 31st Oct 2017 RVX Share Price closed @ 1.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.73 & Strong Sell for SHORT-TERM with Stoploss of 1.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
RVX Target for November
1st Target up-side 1.61
2nd Target up-side 1.82
3rd Target up-side 2.03
1st Target down-side 0.99
2nd Target down-side 0.78
3rd Target down-side 0.57
RVX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.resverlogix.com
RVX Address
RVX
279 Midpark Way S.E.
Suite 202
Calgary, AB T2X 1M2
Canada
Phone: 403-254-9252
Fax: 403-256-8495
RVX Latest News
Interactive Technical Analysis Chart Resverlogix Corp ( RVX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Resverlogix Corp
RVX Business Profile
Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.